Brief Review of Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19— Gordon 2021
This is a brief audio review. In the article Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 published, 2021 by Gordon and Colleagues, The outcomes and key points are as noted: Interleukin 5 receptor antagonists tocilizumab and sarilumab improved outcomes and survival in critically ill patients with COVID19 receiving multi-organ support in the intensive care unit. Median Adjusted Cumulative Odds Ratio 1.64 (95% credible interval, 1.25 to 2.14) for tocilizumab compared to control. Median Adjusted Cumulative Odds Ratio 1.76 (95% credible interval, 1.17 to 2.91) for sarilumab as compared with control. Number needed to treat for survival in critical COVID 19 illness when compared to control: 13 to 1 in the tocilizumab group. 8 to 1 in the sarilumab group. 90-day survival pooled hazard ratio 1.61 (95% credible interval, 1.25 to 2.08) for interleukin-6 receptor antagonists yielding for the comparison with the control group, in a Randomized control trial, multifactorial (adaptive platform trial) with 803 patients who were Patients 18 years or older, with clinically suspected or laboratory confirmed COVID-19, critically ill, and admitted to an intensive care unit and receiving respiratory or cardiovascular organ support, and classified as having severe disease.
Gordon AC, Angus DC, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply. N Engl J Med. 2021 Sep 16;385(12):1147-1149. doi: 10.1056/NEJMc2108482. Epub 2021 Aug 18. PMID: 34407335.
